These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34601988)

  • 21. Expert recommendations on treating psoriasis in special circumstances.
    Carrascosa JM; Belinchón I; de-la-Cueva P; Izu R; Luelmo J; Ruiz-Villaverde R
    Actas Dermosifiliogr; 2015 May; 106(4):292-309. PubMed ID: 25595327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
    Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
    Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reaching Treatment Goals in Psoriasis with Conventional Systemic Drugs: How Long Are We Willing to Wait?
    Jacobi A; Weidemann-Röver B; Barbus S; Mrowietz U
    Dermatology; 2022; 238(2):292-300. PubMed ID: 34107489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
    Gisondi P; Altomare G; Ayala F; Bardazzi F; Bianchi L; Chiricozzi A; Costanzo A; Conti A; Dapavo P; De Simone C; Foti C; Naldi L; Offidani A; Parodi A; Piaserico S; Prignano F; Rongioletti F; Stingeni L; Talamonti M; Girolomoni G
    J Eur Acad Dermatol Venereol; 2017 May; 31(5):774-790. PubMed ID: 28244153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Tan H; Valdez H; Griffins CE; Mrowietz U; Tallman A; Wolk R; Gordon K
    J Dermatolog Treat; 2017 Feb; 28(1):3-7. PubMed ID: 27538247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report.
    Youn SW; Kim BR; Lee JH; Song HJ; Choe YB; Choi JH; Kim NI; Kim KJ; Youn JI
    Ann Dermatol; 2015 Apr; 27(2):184-9. PubMed ID: 25834358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2 - Management of Special Populations, Patients With Comorbid Conditions, and Risk.
    Carrascosa JM; Puig L; Romero IB; Salgado-Boquete L; Del Alcázar E; Lencina JJA; Moreno D; de la Cueva P
    Actas Dermosifiliogr; 2022 Jun; 113(6):583-609. PubMed ID: 35570005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis.
    de la Cueva Dobao P; Notario J; Ferrándiz C; López Estebaranz JL; Alarcón I; Sulleiro S; Borrás J; Daudén E; Carrascosa JM; Sánchez Carazo JL; Monte Boquet E; Puig L
    J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1214-1223. PubMed ID: 31037770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-relevant treatment goals in psoriasis.
    Blome C; Gosau R; Radtke MA; Reich K; Rustenbach SJ; Spehr C; Thaçi D; Augustin M
    Arch Dermatol Res; 2016 Mar; 308(2):69-78. PubMed ID: 26688112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy.
    Carrascosa JM; Puig L; Belinchón Romero I; Salgado-Boquete L; Del Alcázar E; Andrés Lencina JJ; Moreno D; de la Cueva P
    Actas Dermosifiliogr; 2022 Mar; 113(3):261-277. PubMed ID: 35526919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 33. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
    Gordon KB; Reich K; Crowley JJ; Korman NJ; Murphy FT; Poulin Y; Spelman L; Yamauchi PS; Mendelsohn AM; Parno J; Rozzo SJ; Ellis CN
    J Dermatolog Treat; 2022 Feb; 33(1):219-228. PubMed ID: 32349565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus.
    Langley RG; Saurat JH; Reich K;
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):373-81. PubMed ID: 22151734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.
    Grine L; de la Brassinne M; Ghislain PD; Hillary T; Lambert J; Segaert S; Willaert F; ; Lambert J
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):676-684. PubMed ID: 31749264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery.
    Arango C; Fagiolini A; Gorwood P; Kane JM; Diaz-Mendoza S; Sahota N; Correll CU
    BMC Psychiatry; 2023 Jun; 23(1):453. PubMed ID: 37344763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study.
    Caldarola G; Galluzzo M; Bernardini N; Calabrese L; Grimaldi M; Moretta G; Pagnanelli G; Shumak RG; Talamonti M; Tofani L; Pallotta S; Peris K; Potenza C; De Simone C; Campione E
    Dermatol Ther; 2022 Jun; 35(6):e15488. PubMed ID: 35384168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
    De Simone C; Dapavo P; Malagoli P; Martella A; Campanati A; Campione E; Errichetti E; Franchi C; Gambardella A; Megna M; Osti F; Ribero S; Zagni G; Calzavara-Pinton P; Fabbrocini G; ; Amoruso GF; Baglieri F; Biamonte AS; Bianchelli T; Bigi L; Bortoli J; Brunetti B; Buligan C; Cagni E; Calderoni O; Calzavara-Pinton P; Campanati A; Caputo A; Carrera CG; Carugno A; Chersi K; Cicchelli S; De Natale F; De Simone C; Dapavo P; Di Maria D; Errichetti E; Fabbrocini G; Ferrari AS; Fogli E; Forconi R; Franchi C; Galeazzi A; Gambardella A; Giovannini A; Giura MT; Iuculano M; Lazzaretti G; Leporati C; Magnanini M; Malagoli P; Marconi B; Martella A; Maruccia A; Megna M; Miglietta R; Minuti A; Mocci L; Modica S; Narcisi A; Odorici G; Osti F; Pazzaglia M; Peila R; Pertusi G; Pezza M; Pezzullo E; Puccia N; Raulo U; Ribero S; Rossi M; Rusignuolo S; Sapienza G; Savarese C; Scalisi M; Strippoli D; Stroppiana E; Tiberio R; Trischitta A; Tucci MG; Vaira F; Verrone A; Villa L; Zagni F; Zoccali A
    Int J Dermatol; 2022 Dec; 61(12):1543-1551. PubMed ID: 35609147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.